[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Moustafa H, Riad R, Omar W, Zaher A, Ebied E: 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities. Q J Nucl Med; 2003 Mar;47(1):51-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 99mTc-MIBI in the assessment of response to chemotherapy and detection of recurrences in bone and soft tissue tumours of the extremities.
  • AIM: This prospective study is focused on the assessment of tumour response in a group of 28 bone sarcoma patients using (99m)Tc-MIBI scintigraphy.
  • METHODS: The quantitative changes in MIBI uptake before and after chemotherapy were measured and associated with the pathological evaluation of the degree of tumour necrosis.
  • Besides this, another group of 40 patients with bone and soft tissue tumours was studied in order to evaluate the diagnostic efficacy of (99m)Tc-MIBI scintigraphy versus computed tomography (CT) and/or magnetic resonance imaging (MRI) in detecting the status of the disease and its recurrences.
  • Following 3-4 courses of chemotherapy, bone tumours were assessed by comparing the uptake ratio in the viable tumours with the amount of necrotic processes described in the surgically removed specimens.
  • RESULTS: In the first group of patients the rate of tumour response to chemotherapy, calculated according to the percentage of necrosis and the (99m)Tc-MIBI uptake ratios, was as follows: complete response in 12 patients, partial response in 8 and no response in 8 patients.
  • In the second group of patients (40 patients) (99m)Tc-MIBI scintigraphy proved to be able to detect recurrences of bone and soft tissue tumours.
  • CONCLUSION: The application of (99m)Tc-MIBI scan in the management of patients treated with chemotherapy may allow an early identification of the non-responder patients and lead to a choice of different strategies (alternative chemotherapy or salvage surgery).
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radionuclide imaging. Technetium Tc 99m Sestamibi
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Extremities / radionuclide imaging. Female. Giant Cell Tumors / diagnosis. Giant Cell Tumors / drug therapy. Giant Cell Tumors / radionuclide imaging. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / radionuclide imaging. Preoperative Care. Radiopharmaceuticals. Sarcoma / diagnosis. Sarcoma / drug therapy. Sarcoma / radionuclide imaging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12714955.001).
  • [ISSN] 1125-0135
  • [Journal-full-title] The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)
  • [ISO-abbreviation] Q J Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


2. Donthineni R, Boriani L, Ofluoglu O, Bandiera S: Metastatic behaviour of giant cell tumour of the spine. Int Orthop; 2009 Apr;33(2):497-501
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic behaviour of giant cell tumour of the spine.
  • Lung metastases from giant cell tumours (GCT) of the spine have not been specifically addressed in the literature.
  • We reviewed our cases and compared the incidence, treatment, and outcomes with those from the extremities.
  • Four of the seven patients had presented to our institution with a spine recurrence after previous treatments and the rest developed recurrences later.
  • The treatments for the lung nodules consisted of metastectomy in two and chemotherapy in six patients.
  • Our series shows a higher metastatic rate from spine GCT as compared to those from the extremities, but the overall behaviour and treatment outcomes of the lung metastases are similar.
  • When there is a recurrence of GCT, with or without metastases, the local and possibly the metastases should be biopsied to confirm the original diagnosis.
  • Progression of benign GCT into an aggressive sarcoma has been documented, and the method of management should be altered.
  • [MeSH-major] Bone Neoplasms / pathology. Giant Cell Tumor of Bone / secondary. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 2002 Aug;(401):202-8 [12151897.001]
  • [Cites] Int Orthop. 2006 Dec;30(6):499-504 [16909252.001]
  • [Cites] J Bone Joint Surg Am. 1975 Mar;57(2):167-73 [1112843.001]
  • [Cites] Cancer. 1980 Oct 1;46(7):1641-9 [7417958.001]
  • [Cites] J Bone Joint Surg Am. 1984 Feb;66(2):269-74 [6693454.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):204-5 [2249533.001]
  • [Cites] AJR Am J Roentgenol. 1992 Feb;158(2):331-4 [1729794.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jan;75(1):148-54 [8421014.001]
  • [Cites] Clin Orthop Relat Res. 1994 May;(302):219-30 [8168305.001]
  • [Cites] Int Orthop. 1996;20(3):172-6 [8832321.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • [Cites] Clin Orthop Relat Res. 1997 May;(338):205-14 [9170381.001]
  • [Cites] J Bone Joint Surg Br. 1998 Jan;80(1):43-7 [9460951.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Oct;116(4):649-51 [9766596.001]
  • [Cites] Cancer. 1964 Apr;17:461-72 [14136529.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:116-22 [16131879.001]
  • [Cites] J Bone Joint Surg Am. 1970 Jun;52(4):619-64 [5479455.001]
  • (PMID = 18461324.001).
  • [ISSN] 1432-5195
  • [Journal-full-title] International orthopaedics
  • [ISO-abbreviation] Int Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2899057
  •  go-up   go-down


3. Koga F, Kawano K, Honda M, Sumi S, Horimi H, Kondo S, Yoshida K: Sarcomatoid renal cell carcinoma with scant carcinomatous components. Int J Urol; 2000 Feb;7(2):58-60; discussion 61
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid renal cell carcinoma with scant carcinomatous components.
  • On microscopic examination of initial 17 sections, the tumor consisted of pleomorphic giant cells and spindle neoplastic cells.
  • The giant cells were also scatteringly, weakly positive for myoglobin.
  • At that time a diagnosis of rhabdomyosarcoma of the kidney was made.
  • However, further microscopic examination of another eight sections revealed small areas of clear cell-type renal cell carcinoma (RCC) which transited to sarcomatous components and led to a diagnosis of sarcomatoid RCC.
  • The patient underwent three cycles of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Sarcoma / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10710249.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  •  go-up   go-down


Advertisement
4. Burnei G, Burnei C, Hodorogea D, Gavriliu S, Georgescu I, Vlad C: Osteoarticular reconstructive surgery in malignant bone tumors: the importance of external fixators. J Med Life; 2008 Jul-Sep;1(3):295-306
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients with malignant bone tumors (table 1.) were studied by sex, tumor type, location, age at the moment of diagnosis, age at the moment of the last evaluation, type of surgery, external fixator implanted, complications, results and survival period.
  • We also considered for each patient the extent of the tumor to diaphysis, soft tissue involvement, involvement of physis and epiphyseal invasion, articular extent, vessels and nerves invasion, presence of metastases and local skin invasion.
  • The certain diagnosis was based on pathological anatomy exam, because clinical and imagistic data were not decisive in each case.
  • The conservative treatment is preferred to the amputation, which is being used in very few cases.
  • The development of reconstructive bone surgery is sustained by the possibility to delineate the tumor by diagnosis based on imaging and by the possibility to use modern preoperative and postoperative chemotherapy and radiotherapy.
  • Since then the same treatment was preferred also in malignant bone tumors, because the relapse appeared as frequent as in cases with amputation but the physical and psychological comfort made the patients to accept it readily.
  • The goal of malignant bone tumors treatment is to save the life of the patient, to preserve the affected limb, to maintain the length and function of the limb.
  • [MeSH-major] Bone Neoplasms / surgery. Chondrosarcoma / surgery. External Fixators. Giant Cell Tumor of Bone / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Female. Femur / surgery. Humans. Humerus / surgery. Male. Reconstructive Surgical Procedures / methods. Retrospective Studies. Sarcoma, Ewing / surgery. Tibia / surgery. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Orthop. 1987;11(1):35-41 [3549587.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):51-61 [10810462.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1985;71(7):435-50 [3911313.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] J Bone Joint Surg Br. 1995 Jul;77(4):608-14 [7615607.001]
  • [Cites] Ital J Orthop Traumatol. 1975 Apr;1(1):5-22 [1067250.001]
  • [Cites] J Bone Joint Surg Am. 1988 Apr;70(4):507-16 [3281952.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):558-61 [9250738.001]
  • [Cites] J Bone Joint Surg Am. 1990 Mar;72(3):334-45 [2135632.001]
  • [Cites] Clin Orthop Relat Res. 2001 Sep;(390):212-20 [11550868.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):181-96 [1884538.001]
  • [Cites] Int Orthop. 1998;22(1):27-31 [9549578.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1393-9 [4045528.001]
  • [Cites] Int Orthop. 1988;12(1):21-9 [3372098.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] J Bone Joint Surg Am. 1978 Jan;60(1):31-40 [415064.001]
  • [Cites] Acta Orthop Scand. 1989 Apr;60(2):143-53 [2658466.001]
  • [Cites] Int Orthop. 1998;22(5):330-4 [9914940.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • (PMID = 20108507.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


5. Beccheroni A, Lucarelli E, Donati D, Sangiorgi L, Capponcelli S, Gorini M, Zambon Bertoja A, Giardino R, Mercuri M, Ferrari S, Bacci G, Picci P: Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: implication for cell-based therapy in bone defect reconstruction. Oncol Rep; 2003 Jul-Aug;10(4):891-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recovery of stromal stem cells in bone sarcoma patients after chemotherapy: implication for cell-based therapy in bone defect reconstruction.
  • Bone sarcomas, such as osteosarcoma (OS) or Ewing sarcoma (ES), frequently arise in the intramedullary region of long bones.
  • Patients affected by bone sarcomas are treated with preoperative aggressive chemotherapy immediately after diagnosis.
  • After chemotherapy, patients undergo surgery that frequently entails the excision of wide bone segments.
  • Because bone marrow derived stromal stem cells (SSC) offer great promise for cell-based regenerative medicine in bone reconstruction, we investigated whether SSC could be isolated from chemotherapy-treated bone sarcoma patients.
  • We also investigated whether chemotherapy modified SSC differentiation capability.
  • We studied 9 SSC derived from OS and ES patients that had undergone chemotherapy and 5 SSC derived from bone sarcoma patients that had not undergone chemotherapy.
  • SSC could be obtained from all the patients analyzed regardless of whether the patients received chemotherapy or not.
  • Our results also showed that post-chemotherapy SSC can be cultured and expanded ex vivo, these cells retained the ability to differentiate toward the osteogenic lineage in vitro.
  • In conclusion, our results support that SSC cells can be obtained from bone sarcoma patients that undergo chemotherapy and suggest that SSC can be used for cell-based bone reconstruction techniques in bone sarcoma patients treated with preoperative chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / pathology. Neoplastic Stem Cells / pathology. Osteoblasts / pathology. Stromal Cells / pathology
  • [MeSH-minor] Adolescent. Adult. Cell Differentiation. Cell Division. Cells, Cultured. Child. Chondrosarcoma / drug therapy. Chondrosarcoma / metabolism. Chondrosarcoma / pathology. Female. Giant Cell Tumors / drug therapy. Giant Cell Tumors / metabolism. Giant Cell Tumors / pathology. Humans. Male. Osteosarcoma / drug therapy. Osteosarcoma / metabolism. Osteosarcoma / pathology. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792741.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


6. Loi S, Goldstein D, Clezy K, Milliken ST, Hoy J, Chipman M: Castleman's disease and HIV infection in Australia. HIV Med; 2004 May;5(3):157-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: HIV-infected patients diagnosed with MCD since 1994, were identified from three major HIV treatment centres in Australia.
  • All had CD4 cell counts less than 500 cells/microL.
  • All but one patient was receiving HAART at the time of diagnosis.
  • Nine of the 11 patients had Kaposi's sarcoma (KS) and two patients also developed non-Hodgkin's Lymphoma (NHL).
  • All patients received chemotherapy for MCD.
  • The response rate from Chemotherapy was 64%.
  • There is limited recent information on optimal treatment for MCD.
  • In our experience, treatment with liposomal anthracycline was associated with good response rates and acceptable toxicity in several patients, and therefore merits further exploration to establish its role.
  • Treatment in the future may concentrate on novel agents such as anti-interleukin 6, anti-CD20 antibodies, thalidomide and viral ablation.
  • [MeSH-major] Giant Lymph Node Hyperplasia / virology. HIV Infections / complications
  • [MeSH-minor] Adult. Alkylating Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Victoria / epidemiology

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15139981.001).
  • [ISSN] 1464-2662
  • [Journal-full-title] HIV medicine
  • [ISO-abbreviation] HIV Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkylating Agents
  •  go-up   go-down


7. Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, Heymann D: Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer; 2005;5:123
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.
  • BACKGROUND: Osteosarcoma is the most common type of primary bone tumor.
  • The use of aggressive chemotherapy has drastically improved the prognosis of the patients with non-metastatic osteosarcomas, however the prognosis of the patients with metastasis is still very poor.
  • Then, new and more effective treatments for curing osteosarcoma, such as immunotherapy are needed.
  • Tumor-infiltrating lymphocytes (TIL) have been involved in the control of tumor development and already assessed with success for the treatment of several cancers including melanoma.
  • While TIL represent a fascinating therapeutic approach in numerous malignant pathologies, there is few report concerning adult bone-associated tumors including osteosarcoma.
  • METHODS: Human TIL were isolated and characterized (phenotype, lytic activity) from twenty-seven patients with bone-associated tumors (osteosarcoma, Ewing's sarcoma, giant cell tumor, chondrosarcoma, plasmocytoma and bone metastases).
  • RESULTS: While TIL with a main CD4+ profile were easily isolated from most of the tumor samples, only TIL extracted from osteosarcoma were cytotoxic against allogeneic tumor cells.
  • CONCLUSION: These results demonstrated that TIL therapy could be a very efficient strategy for the treatment of adult osteosarcoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. CD4-Positive T-Lymphocytes / cytology. Cell Line, Tumor. Disease Models, Animal. Female. Flow Cytometry. Humans. Immunotherapy / methods. Leukocytes / pathology. Lymphocytes, Tumor-Infiltrating / cytology. Male. Melanoma / pathology. Middle Aged. Neoplasm Metastasis. Phenotype. Prognosis. Rats

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1999 Nov;12(11):1050-6 [10574602.001]
  • [Cites] Cancer Immunol Immunother. 2006 Apr;55(4):451-8 [16034562.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):29-32 [10853014.001]
  • [Cites] Pediatr Hematol Oncol. 2000 Jul-Aug;17(5):355-64 [10914045.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] J Orthop Res. 2001 May;19(3):346-51 [11398844.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):963-70 [11549589.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 [11734652.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3950-62 [11751487.001]
  • [Cites] Cancer Immunol Immunother. 2002 Nov;51(10):539-46 [12384805.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):332-42 [12843795.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):53-7 [14736523.001]
  • [Cites] Intern Med. 2004 Apr;43(4):323-6 [15168777.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5442-8 [15289353.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Int J Cancer. 1977 Jul 15;20(1):112-9 [269099.001]
  • [Cites] Science. 1986 Sep 19;233(4770):1318-21 [3489291.001]
  • [Cites] J Biol Response Mod. 1990 Apr;9(2):149-59 [1971302.001]
  • [Cites] Eur J Immunol. 1991 Jun;21(6):1403-10 [1904359.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 3;83(13):932-7 [2067036.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Cancer Immunol Immunother. 1992;34(4):241-51 [1311218.001]
  • [Cites] Cancer Immunol Immunother. 1994 May;38(5):332-8 [8162615.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 [8028037.001]
  • [Cites] Immunol Rev. 1995 Jun;145:167-77 [7590825.001]
  • [Cites] Ann Surg Oncol. 1996 Nov;3(6):580-7 [8915492.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] J Orthop Res. 1997 Jan;15(1):128-32 [9066537.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):543-7 [9352689.001]
  • [Cites] Pathol Res Pract. 1998;194(10):679-84 [9820863.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2A):1137-42 [10368665.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):721-6 [10505031.001]
  • [Cites] Cancer Biother Radiopharm. 2004 Dec;19(6):730-7 [15665620.001]
  • [Cites] J Immunol. 2005 Mar 1;174(5):2591-601 [15728465.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):2026-34 [15753403.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2457-64 [15781662.001]
  • [Cites] J Immunother. 2005 May-Jun;28(3):258-67 [15838383.001]
  • [Cites] J Immunol. 2005 May 15;174(10):5959-67 [15879088.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):3998-4004 [15899788.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1754-63 [15902685.001]
  • [Cites] Oncol Rep. 2005 Sep;14(3):763-9 [16077989.001]
  • [Cites] Tumori. 2000 Jan-Feb;86(1):46-52 [10778766.001]
  • (PMID = 16188028.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1262697
  •  go-up   go-down


8. Bower M: How I treat HIV-associated multicentric Castleman disease. Blood; 2010 Nov 25;116(22):4415-21
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HIV-associated plasmablastic multicentric Castleman disease is an increasingly frequent diagnosis.
  • Kaposi sarcoma herpesvirus is found in the monotypic polyclonal plasmablasts that characterize this disease.
  • Unlike Kaposi sarcoma, the incidence does not correlate with CD4 cell count or use of highly active antiretroviral therapy.
  • It is a relapsing and remitting illness, and diagnostic criteria are emerging that define disease activity based on the presence of a fever and raised C-reactive protein coupled with a list of clinical features.
  • Treatment protocols increasingly stratify therapy according to performance status and organ involvement.
  • I advocate rituximab monotherapy for good performance status patients without organ involvement and rituximab with chemotherapy for more aggressive disease.
  • The success of antiherpesvirus agents in controlling active disease is limited, but valganciclovir may have a role as maintenance therapy in the future.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / therapeutic use. HIV Infections / complications
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antiretroviral Therapy, Highly Active. Antiviral Agents / therapeutic use. Giant Lymph Node Hyperplasia / drug therapy. Giant Lymph Node Hyperplasia / etiology. Giant Lymph Node Hyperplasia / pathology. Giant Lymph Node Hyperplasia / prevention & control. Humans. Recurrence. Rituximab

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20688959.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / tocilizumab; 4F4X42SYQ6 / Rituximab; Multi-centric Castleman's Disease
  •  go-up   go-down


9. Gérard L, Bérezné A, Galicier L, Meignin V, Obadia M, De Castro N, Jacomet C, Verdon R, Madelaine-Chambrin I, Boulanger E, Chevret S, Agbalika F, Oksenhendler E: Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol; 2007 Aug 1;25(22):3350-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.
  • PURPOSE: Single-agent chemotherapy is usually effective in HIV-associated multicentric Castleman's disease (MCD).
  • However, in most patients, chemotherapy cannot be discontinued.
  • PATIENTS AND METHODS: To evaluate the efficacy of four weekly rituximab infusions (375 mg/m(2)) after discontinuation of chemotherapy in HIV-associated MCD, 24 patients were enrolled onto a prospective open-label trial.
  • RESULTS: At study entry, the median time from MCD diagnosis was 21 months.
  • All patients had stable disease on chemotherapy and were dependent on chemotherapy for a median time of 13 months.
  • The median CD4 cell count was 270 x 10(6)/L, and the plasma HIV RNA was less than 50 copies/mL in 18 patients.
  • Sustained remission (SR) off treatment at day 60 (primary end point) was achieved in 22 patients (92%).
  • Seventeen patients (71%) were alive in SR at day 365 without specific treatment, and the overall survival rate was 92% (95% CI, 71% to 98%).
  • Mild exacerbation of Kaposi's sarcoma (KS) lesions was observed in eight of 12 patients with previous KS.
  • CONCLUSION: Rituximab was both effective and safe in HIV-infected patients with chemotherapy-dependent MCD.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Giant Lymph Node Hyperplasia / complications. Giant Lymph Node Hyperplasia / drug therapy. HIV Infections / complications
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Polymerase Chain Reaction. Prospective Studies. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - Multicentric Castleman's Disease.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17664482.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


10. Gironet N, De Muret A, Machet L, Diot P, Rivollier C, Dumont P, Lorette G, Vaillant L: [Paraneoplastic pemphigus revealing dendritic cell sarcoma originating from Castleman's disease of the neck]. Ann Dermatol Venereol; 2005 Jan;132(1):41-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Paraneoplastic pemphigus revealing dendritic cell sarcoma originating from Castleman's disease of the neck].
  • [Transliterated title] Pemphigus paranéoplasique révélateur du développement d'un sarcome à cellules dendritiques à partir d'une tumeur de Castleman pulmonaire.
  • The search for intercellular anti-substance antibodies on rat spleen was positive, corresponding to anti-envoplakin IgG and leading to the diagnosis of paraneoplastic pemphigus.
  • The thoracic x-ray and scan revealed a hilum tumor, the histological examination of which confirmed the diagnosis of Castleman's disease concomitant to sarcomatous transformation.
  • Following surgical treatment, the respiratory failure worsened.
  • The patient improved with systemic corticosteroids at the dose of 2 mg/kg/d and chemotherapy was initiated.
  • The transformation of the Castleman tumor into a sarcoma may have unmasked intra-cellular antigens (plakins), initiating the specific immune reaction.
  • [MeSH-major] Giant Lymph Node Hyperplasia / complications. Paraneoplastic Syndromes / etiology. Pemphigus / etiology. Sarcoma / complications. Sarcoma / etiology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Dendritic Cells. Diagnosis, Differential. Fatal Outcome. Humans. Male. Oral Ulcer / etiology. Oral Ulcer / pathology. Respiratory Insufficiency

  • Genetic Alliance. consumer health - Castleman's Disease.
  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746607.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


11. Audouin J, Vercelli-Retta J, Le Tourneau A, Adida C, Camilleri-Broët S, Molina T, Diebold J: Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis. Pathol Res Pract; 2003;199(2):107-12
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis.
  • We report an exceptional case of a histiocytic sarcoma presenting as a primary isolated spleen tumor in a 71-year-old woman.
  • The medium cells, large cells and the giant cells expressed CD68, a histiocyte-associated marker, lysozyme and S100 protein.
  • All these cells were negative for B- and T-cell markers, cytokeratins, melanosome markers (HMB45) and CD1a (Langerhans' cells).
  • Despite multi-agent chemotherapy, the patient suffered from a relapse in the liver, with a rapid fatal outcome.
  • The association with a reactive histiocytosis with erythrophagocytosis corresponds to "histiocytic medullary reticulosis", as previously described by Scott and Robb-Smith.
  • [MeSH-major] Histiocytic Sarcoma / pathology. Sarcoma / complications. Sarcoma / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Inflammation / metabolism. Inflammation / pathology. Liver Neoplasms / secondary. Lymph Nodes / pathology

  • Genetic Alliance. consumer health - Histiocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12747473.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Yin WH, Yu GY, Ma Y, Rao HL, Lin SX, Shao CK, Liang Q, Guo N, Chen GQ, Zhou W, Zhao T, Zhu MG: [Follicular dendritic cell sarcoma: a clinicopathologic analysis of ten cases]. Zhonghua Bing Li Xue Za Zhi; 2010 Aug;39(8):522-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Follicular dendritic cell sarcoma: a clinicopathologic analysis of ten cases].
  • OBJECTIVE: To study the clinicopathologic features of follicular dendritic cell sarcoma (FDCS) and its differential diagnosis.
  • Multinucleated tumor giant cells and intranuclear pseudoinclusions were occasionally seen.
  • The remaining 5 patients were alive and disease-free after surgical excision (+/- chemotherapy and radiotherapy).
  • Appropriate application of FDC markers, such as CD21, CD35 and D2-40, would be helpful for arriving at a correct diagnosis.
  • Most cases are associated with good prognosis after surgical treatment, with or without chemotherapy and radiotherapy.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / pathology. Lymph Nodes / pathology. Tonsillar Neoplasms / pathology
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived / metabolism. Dendritic Cell Sarcoma, Interdigitating / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Meningioma / pathology. Middle Aged. Nasopharyngeal Neoplasms / pathology. Paraneoplastic Syndromes / complications. Pemphigus / complications. Receptors, Complement 3b / metabolism. Receptors, Complement 3d / metabolism. Receptors, IgE / metabolism. Young Adult

  • Genetic Alliance. consumer health - TEN.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21055030.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Receptors, Complement 3b; 0 / Receptors, Complement 3d; 0 / Receptors, IgE; 0 / monoclonal antibody D2-40
  •  go-up   go-down


13. Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, Yano T: In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res; 2001 Nov-Dec;21(6A):4147-51
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro chemosensitivity of human soft tissue sarcoma.
  • Chemotherapy is essential in the treatment of small round cell sarcomas.
  • However, as yet there is no progress concerning the efficacy of chemotherapy in the treatment of other types of soft tissue tumors (STS).
  • The Histoculture Drug Response Assay (HDRA) is an in vitro chemosensitivity test that has a high correlation with clinical response, the usefulness of which has been reported in various kinds of solid tumors.
  • Drug sensitivity testing by HDRA showed that two drugs, ADM and THP, had a significantly higher inhibitory rate than CDDP, IFOS, or VP-16 in the thirty-three soft tissue sarcomas tested.
  • Depending on the morphological type, spindle cell sarcomas were sensitive to THP, which showed significantly higher inhibition rates than CDDP, IFOS, or VP-16.
  • Small round cell sarcomas were relatively sensitive to all of the drugs tested.
  • However the drug sensitivity of pleomorphic cell sarcoma was low except for ADM and THP, while its sensitivity to THP was higher than about 70%.
  • However, there are numerous other soft tissue sarcomas that do not belong to these categories; drug sensitivity testing in each of them and the devising of individualized treatment strategies seems necessary to improve the therapeutic outcome.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Doxorubicin / analogs & derivatives. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Humans

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911309.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


14. Miyagi T, Nagasaki A, Shinzato O, Ohshima K, Takasu N: [Interdigitating dendritic cell sarcoma/tumor--a case report]. Gan To Kagaku Ryoho; 2007 Mar;34(3):469-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma/tumor--a case report].
  • We report an extremely rare case of interdigitating dendritic cell sarcoma/tumor (IDCS).
  • A 52-year-old man presented with a 2-week history of fever in January 2002.
  • Whole-body computerized tomography showed enlarged lymph nodes in mediastinal, right axillary, abdominal para-aortic, ileum, and inguinal regions.
  • Spindle shape cells and Hodgkin-like giant cells were also seen.
  • These findings were compatible with the diagnosis of IDCS.
  • However, he developed fungal pneumonia and died of respiratory failure 1 month after the start of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dendritic Cells / pathology. Lymph Nodes / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Hepatomegaly / pathology. Humans. Male. Middle Aged. Prednisone / administration & dosage. Rare Diseases. Splenomegaly / pathology. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353646.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


15. Rocha LA, Rizo VH, Romañach MJ, de Almeida OP, Vargas PA: Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature.
  • Alveolar soft-part sarcoma (ASPS) is a rare malignant neoplasm with uncertain histogenesis and with a distinctive morphology.
  • A 27-year-old male patient, who was under chemotherapy treatment for ASPS of the thigh, presented in our dental clinic with a painless and pedunculated nodule on the right tuber maxillae.
  • An incisional biopsy was performed and the diagnosis of metastatic ASPS was made.
  • Unfortunately, the patient died 2 months after the diagnosis of the oral metastasis.
  • [MeSH-major] Gingival Neoplasms / secondary. Maxilla / pathology. Sarcoma, Alveolar Soft Part / secondary
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleolus / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Diagnosis, Differential. Fatal Outcome. Gingival Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Male. Muscle Neoplasms / pathology. Thigh / pathology

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303057.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • To characterize these tumors further, 14 extranodal histiocytic sarcomas were analyzed.
  • All patients presented with a solitary mass, ranging in size from 1.8 to 12 cm (median 6.8 cm).
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Binucleated cells were common, and 6 cases contained tumor giant cells.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.
  • Histiocytic sarcoma has the potential for an aggressive clinical course, most often with lymph node involvement.
  • [MeSH-major] Sarcoma / pathology

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Singer FR: Paget disease: when to treat and when not to treat. Nat Rev Rheumatol; 2009 Sep;5(9):483-9
MedlinePlus Health Information. consumer health - Paget's Disease of Bone.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients are often asymptomatic, but a subset experience considerable morbidity that can include bone pain and skeletal deformity, as well as a variety of regional complications, such as hearing loss associated with cranial involvement, degenerative arthritis of the hip or knee, fractures of the lower extremities and, rarely, sarcoma or giant cell tumors.
  • Future studies are needed to determine whether these drugs, if used in an early stage of the disease, can prevent complications in asymptomatic patients.
  • [MeSH-major] Diphosphonates / therapeutic use. Osteitis Deformans / drug therapy
  • [MeSH-minor] Bone Density Conservation Agents / therapeutic use. Humans. Incidental Findings. Osteoclasts / drug effects. Osteogenesis / drug effects. Osteolysis / drug therapy. Pain / prevention & control

  • Genetic Alliance. consumer health - Paget Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652650.001).
  • [ISSN] 1759-4804
  • [Journal-full-title] Nature reviews. Rheumatology
  • [ISO-abbreviation] Nat Rev Rheumatol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates
  • [Number-of-references] 71
  •  go-up   go-down


18. Shiomi T, Yamamoto T, Manabe T: Mycobacterial spindle cell pseudotumor of the skin. J Cutan Pathol; 2007 Apr;34(4):346-51
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mycobacterial spindle cell pseudotumor of the skin.
  • BACKGROUND: Mycobacterial spindle cell pseudotumor is a rare tumor-like lesion characterized by the proliferation of spindle cells engorged with mycobacterial microorganisms.
  • CASE REPORT: A 58-year-old Japanese woman presented with a nodule in her left forearm.
  • She was also receiving insulin treatment for diabetes mellitus.
  • RESULTS: Histologically, the lesion was located in the deep dermis with extension into the subcutaneous fat tissue and was composed mainly of spindle cells focally showing a vaguely storiform pattern.
  • In limited focal areas, foam cells, epithelioid histiocytes, and multinucleated giant cells were seen sparsely.
  • CONCLUSIONS: We emphasize that mycobacterial spindle cell pseudotumor should be included in the differential diagnoses of a spindle cell lesion in the skin, especially in immunosuppressed patients.
  • [MeSH-major] Mycobacterium avium-intracellulare Infection / pathology. Sarcoma / pathology. Skin Neoplasms / microbiology. Skin Neoplasms / pathology
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Diabetes Mellitus. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lung Diseases, Interstitial / complications. Lung Diseases, Interstitial / drug therapy. Lupus Erythematosus, Systemic / complications. Lupus Erythematosus, Systemic / drug therapy. Middle Aged. Prednisolone / therapeutic use

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381807.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


19. Tuncbilek N, Karakas HM, Okten OO: Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. Eur J Radiol; 2005 Mar;53(3):500-5
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors.
  • PURPOSE: The value of the dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) in differentiating benign and malignant soft tissue tumors was investigated.
  • MATERIALS AND METHODS: Turbo FLASH DCE-MRI was performed on 22 subjects (2-74 years) with soft tissue tumors.
  • RESULTS: Diagnosis of benign (N = 10) tumors were hemangioma (n = 3), neurogenic tumor (n = 3) lipoma (n = 2), giant cell tumor (n = 1) and desmoid (n = 1), whereas malignant lesions (N = 12) were classified as liposarcoma (n = 5), malignant fibrous histiocytoma (n = 5) and synovial sarcoma (n = 2).
  • CONCLUSION: DCE-MRI parameters that thought to be the surrogate markers of tumoral microcirculation and tissue perfusion provides a specific preoperative diagnosis.
  • Dynamic imaging parameters are therefore advocated for monitoring the effect of chemotherapy in soft tissue tumors.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Contrast Media. Diagnosis, Differential. Discriminant Analysis. Female. Humans. Infant. Logistic Models. Male. Meglumine. Middle Aged. Organometallic Compounds. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741025.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 0 / gadoterate meglumine; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


20. Kapukaya A, Subaşi M, Kandiya E, Ozateş M, Yilmaz F: Limb reconstruction with the callus distraction method after bone tumor resection. Arch Orthop Trauma Surg; 2000;120(3-4):215-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All of the tumors were localised on the femur, and the histological diagnosis was two chondrosarcomas, one Ewing's sarcoma, three osteosarcomas, one giant cell bone tumor, and the remainder benign fibrous histiocytoma.
  • Preoperative and postoperative chemotherapy were applied to patients with osteosarcoma and Ewing's sarcoma.
  • [MeSH-major] Chondrosarcoma / surgery. Femoral Neoplasms / surgery. Giant Cell Tumors / surgery. Histiocytoma, Benign Fibrous / surgery. Osteogenesis, Distraction. Osteosarcoma / surgery. Sarcoma, Ewing / surgery
  • [MeSH-minor] Adolescent. Adult. Bone Transplantation. Child. External Fixators. Female. Femur / radiography. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Time Factors. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10738888.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


21. Waterston A, Bower M: Fifty years of multicentric Castleman's disease. Acta Oncol; 2004;43(8):698-704
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, Castleman's disease is divided into the hyalinized vascular form and a plasma cell variant, the former being more common in localized disease and the latter more common in MCD.
  • MCD is associated with Kaposi's sarcoma herpesvirus (KSHV) infection, which is alternatively termed human herpesvirus 8 (HHV8).
  • The diagnosis of Castleman's disease is established by biopsy and treatment is often based on published case reports only, as there are no randomized trials of therapy.
  • Systemic treatments for MCD have included chemotherapy, anti-herpesvirus treatments to reduce the KSHV viral load, highly active antiretroviral therapy (HAART) to reduce HIV viraemia and latterly monoclonal antibodies against both IL 6 and CD20.
  • Optimization and consensus in treatment of these patients remains a target for the future.
  • [MeSH-major] Giant Lymph Node Hyperplasia / diagnosis. Herpesvirus 8, Human / isolation & purification. Interleukin-6 / analysis. Sarcoma, Kaposi / diagnosis
  • [MeSH-minor] Aged. Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / methods. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Prognosis. Risk Assessment. Severity of Illness Index. Viral Load


22. Seo JB, Im JG, Goo JM, Chung MJ, Kim MY: Atypical pulmonary metastases: spectrum of radiologic findings. Radiographics; 2001 Mar-Apr;21(2):403-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A detailed knowledge of the atypical radiologic features of a pulmonary metastasis with a good understanding of the histopathologic background is essential for correct diagnosis.
  • Squamous cell carcinoma is regarded as the most common cell type of a cavitating metastasis, but metastatic nodules from adenocarcinomas and sarcomas also cavitate occasionally.
  • Calcification can occur in a metastatic sarcoma or adenocarcinoma, which makes differentiation from a benign granuloma or hamartoma difficult.
  • Even though tumor emboli in pulmonary arteries can be seen at computed tomography, diagnosis is difficult because they are located in small or medium arteries.
  • Dilated vascular structures within the mass can be seen in metastatic sarcomas.
  • A sterilized metastasis after chemotherapy is radiologically indistinguishable from a residual viable tumor.
  • Benign tumors such as uterine leiomyomas and giant cell tumors of the bone rarely metastasize to the lung.
  • [MeSH-major] Lung Neoplasms / secondary. Tomography, X-Ray Computed
  • [MeSH-minor] Calcinosis / pathology. Calcinosis / radiography. Diagnosis, Differential. Humans. Lung / pathology. Lung / radiography. Pneumothorax / pathology. Pneumothorax / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11259704.001).
  • [ISSN] 0271-5333
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


23. Zhao J, Wang MZ, Li LY, Zhang L, Zhong W: [Clinical features of pulmonary malignancies in patients younger than 30 years of age]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Apr;32(2):174-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mean time from the onset of disease to confirmed diagnosis was (5.98+/-8.95) months.
  • The proportions of advanced-stage patients (stage III B and IV) and moderate to poor-differentiated tumor accounted for 59.26% (16/27) and 77.8% (14/18), respectively in 27 patients with non-small cell lung cancer.
  • The proportion of tumors in limited stage was 72.73% in 11 patients with small cell lung cancer, and most patients (54.55) were not sensitive to conventional chemotherapy.
  • In 6 patients with carcinoid, 4 patients were central and the other 2 patients were peripheral, and all of them presented as Cushing syndrome; CgA, AE1/AE3, Syn, and NSE were positive in immunohistochemical staining; and surgical operation was the main treatment for them.
  • In 6 patients with carcinomas of salivary gland type, all cases were central; no lymph nodes metastasis was found in the postoperative specimen; and surgical operation was also the main treatment for these patients.
  • Multiple nodules in bilateral lungs were presented in 2 patients with anaplastic large cell lymphomas, in which CD30 was positive in tumor cells; chemotherapy was the main therapy for these two patients.
  • In one patient with synovial sarcoma, the tumor was giant and highly malignant and invasive; it was divided into many cavities filled with bloody fluid and white cheese-like substances; immunohistochemical analysis showed positive vimentin and AE1/AE3.
  • The treatment strategy should be based on the specific conditions of each patient.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450548.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Antonescu CR, Rosenblum MK, Pereira P, Nascimento AG, Woodruff JM: Sclerosing epithelioid fibrosarcoma: a study of 16 cases and confirmation of a clinicopathologically distinct tumor. Am J Surg Pathol; 2001 Jun;25(6):699-709
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sclerosing epithelioid fibrosarcoma (SEF) is an uncommon tumor of deep soft tissues, originally described in 1995 by Meis-Kindblom et al.
  • Treatment consisted of intralesional excision (n = 2), attempted wide local excision (n = 11), and amputation (n = 3), with either adjuvant radiation therapy (n = 9) or chemotherapy (n = 3).
  • Eight patients (57%) died of disease 16 to 86 months after diagnosis.
  • SEF shares some pathologic features with two other fibrosing fibrosarcomas, low-grade fibromyxoid sarcoma and hyalinizing spindle cell tumor with giant rosettes, but in the authors' experience behaves clinically as a fully malignant sarcoma.
  • [MeSH-major] Fibrosarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395547.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Neoplasias neonatales: experiencia de un centro.
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • Males accounted for 43.8 % and females for 56.2 %, with a mean age at diagnosis of 5.5 days (range 1-28 days).
  • Five neonates (31.2 %) had a prenatal diagnosis, 60 % of which were made in the last 7 years of the study period.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • CONCLUSIONS: The neoplasms most frequently diagnosed in the neonatal period were solid tumors, mainly neuroblastoma and teratomas/germ cell tumors; 12.5 % were associated with syndromes or congenital anomalies.
  • In the last 7 years, the prenatal diagnosis of these entities has improved.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 12 males and 11 females with a median age at RT of 6.6 years (range, 2 months to 20 years).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • Median RT dose was 45 Gy (range, 12.3 to 60 Gy) using 4 MV in 9, 1.25 MV in 8, 250 KV in 4, and 6 MV photons in 1 patient.
  • Fourteen had chemotherapy.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15804994.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement